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Simple Summary: The risk assessment of pulmonary nodules on chest computed tomography (CT)
is key to the early detection of lung cancer. Whereas a nodule’s morphological characteristics are
strong predictors of malignancy for that individual nodule, it remains unclear whether the frequency
and CT features of pulmonary nodules contribute to the prediction accuracy of future development of
LC in another location. This was found by performing risk prediction modelling using age, sex, and
CT measures from lung-cancer-free scans as predictors. We found that a greater number of part-solid
and ground-glass nodules in the earliest scan was linearly associated with a higher risk of lung cancer
developing in another location in the future. There were also indications that CT biomarkers of other
pulmonary and heart diseases are risk factors for lung cancer. Our findings endorse the utilization of
information from the entire scan to improve the accuracy of lung risk assessment.
Abstract: The purpose of this case–cohort study was to investigate whether the frequency and
computed tomography (CT) features of pulmonary nodules posed a risk for the future development
of lung cancer (LC) at a different location. Patients scanned between 2004 and 2012 at two Dutch
academic hospitals were cross-linked with the Dutch Cancer Registry. All patients who were diag-
nosed with LC by 2014 and a random selection of LC-free patients were considered. LC patients who
were determined to be LC-free at the time of the scan and all LC-free patients with an adequate scan
were included. The nodule count and types (solid, part-solid, ground-glass, and perifissural) were
recorded per scan. Age, sex, and other CT measures were included to control for confounding factors.
The cohort included 163 LC patients and 1178 LC-free patients. Cox regression revealed that the
number of ground-glass nodules and part-solid nodules present were positively correlated to future
LC risk. The area under the receiver operating curve of parsimonious models with and without
nodule type information were 0.827 and 0.802, respectively. The presence of subsolid nodules in a
clinical setting may be a risk factor for future LC development in another pulmonary location in a
dose-dependent manner. Replication of the results in screening cohorts is required for maximum
utility of these findings.
Keywords: computed tomography; lung neoplasm; biomarkers; epidemiology; risk
1. Introduction
Lung cancer (LC) is the top cause of cancer deaths worldwide, responsible for 2.1 mil-
lion deaths in 2018 [1]. A number of 57% of the patients are diagnosed with metastatic
disease, for which the 5-year survival rate is approximately 5% [2]. The early diagnosis of
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lung cancer almost always involves the early detection and risk assessment of pulmonary
nodules on chest computed tomography (CT).
Based on their CT attenuation, lung nodules are categorized as either solid or subsolid
(SSN). The great majority of lung nodules are solid with a density in the range of other soft
tissue structures, such as muscles. They are very common in a screening population of
people that have been smoking for a number of years [3–7]. SSNs are divided into pure
ground-glass and part-solid nodules: ground-glass nodules have a vaguely increased CT
attenuation, which preserves the visibility of bronchial and vascular margins; part-solid
nodules have a ground-glass as well as a solid component.
Prior studies have shown that SSNs are less prevalent but at greater risk of being
or becoming malignant compared to solid nodules [8–10]. To date, one study in a LC
screening setting reported that the presence of SSNs might be a risk factor for LC develop-
ment in another location in the lungs [4]. The main goal of our study was to attempt to
reproduce these findings in a clinical setting, which may consist of any members from the
general population rather than a high-risk population eligible for screening. Namely, we
investigated whether the presence and frequency of certain nodule types in a baseline CT
scan can predict the development of a LC that has not yet (visibly) originated, and what
the added value of this information is on top of other LC risk predictors.
2. Materials and Methods
2.1. Study Population
Anonymized patient information and CT scans from between January 2004 and
December 2012 were collected from all patients 40 years or older from the University
Medical Center Utrecht (Center A) and Radboud University Medical Center (Center B)
in the Netherlands. These data were cross-referenced with the Dutch Cancer Registry to
determine the patients who were diagnosed with LC up to December 2014. Informed
consent was waived by the institutional review board.
All CT scans from patients diagnosed with LC were retrieved, and the earliest available
CT scan from a sample of approximately three times as many LC-free patients was selected
at random. Patients and/or scans were subsequently excluded if there were image-retrieval
errors, if the image was considered to be of too low quality by a radiologist, if the scan-slice
thickness was greater than 3 mm, or if no scan was available at least 2 months prior to
the LC diagnosis; the latter criteria was selected arbitrarily to be able to ensure the correct
identification of the malignant nodule without excluding too many patients.
2.2. CT Features
All collected scans from Centers A and B were assessed independently by radiologists
O.M.M (9 years’ experience) and E.T.S. (>20 years’ experience), respectively. Their first task
was to extract CT features as given in Table 1, which can be divided into two groups: nodule-
type variables and control variables, the latter of which was used to adjust for potential
confounding. Dedicated in-house software (version 19.9 of CIRRUS Lung Screening, DIAG,
Radboudumc, Nijmegen, The Netherlands) was applied to the scans to automatically detect
and volumetrically segment pulmonary nodules. The radiologists had to either accept or
reject non-calcified nodule candidates provided by the software, and were additionally
required to manually scroll through the full scan for potential nodules which had been
missed by the software. Only nodules that would trigger a follow-up scan according
to nodule management recommendations [11–13] (BTS, LUNG RADS, Fleischner) and
perifissural nodules (PFN) were included in the analysis [14]; nodules related to an obvious
infection (multifocal, unclearly defined, or confluent SSNs) were excluded [15].
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Table 1. Cohort demographics.
Variable Type Categories Lung Cancer Patients(n = 163)
Lung-Cancer-Free
Patients (n = 1178)
Control patient characteristics
Age at earliest scan, years Continuous N/A 64 (58–69) 61 (52–70)
Sex (male) Binary 1 = Male; 0 = Female 100 (61) 685 (58)
Control CT features
Emphysema Binary 1 = Mild, moderate, orsevere; 0 = None 88 (54) 307 (26)
Bronchitis Binary 1 = Yes; 0 = No 68 (42) 287 (24)
Interstitial lung disease Binary 1 = Yes; 0 = No 10 (6) 19 (2)
Lymphadenopathy Binary 1 = Yes; 0 = No 48 (29) 198 (17)
Aortic calcifications Binary 1 = Mild, moderate, orsevere; 0 = None 107 (66) 492 (42)
Coronary calcifications Binary 1 = Mild, moderate, orsevere; 0 = None 115 (71) 582 (49)
Nodule present Binary 1 = Yes; 0 = No 132 (81) 522 (44)
Mean diameter of largest
nodule, mm Continuous N/A 9.0 (6.3–14.6) 6.8 (5.0–12.4)
Nodule type variables
Largest nodule is a SSN Binary 1 = Yes; 0 = No 36/132 (27) 102/522 (20)
Solid nodule present Binary 1 = Yes; 0 = No 105 (64) 365 (31)
Solid nodule count Continuous N/A 1 (1–2) 1 (1–3)
Part-solid nodule present Binary 1 = Yes; 0 = No 18 (11) 43 (4)
Part-solid nodule count Continuous N/A 1 (1–1) 1 (1–1)
Ground-glass nodule
present Binary 1 = Yes; 0 = No 31 (19) 96 (8)
Ground-glass nodule
count Continuous N/A 1 (1–1) 1 (1–2)
Perifissural nodule
present Binary 1 = Yes; 0 = No 16 (10) 166 (14)
Perifissural nodule count Continuous N/A 1 (1–1) 1 (1–1)
Values given in brackets are percentages for binary variables and twenty-fifth and seventy-fifth percentiles for continuous variables. For
continuous variables, only values greater than zero were summarized. N/A: not applicable.
Each nodule was given a unique ID; this enabled the radiologists to retrospectively
assess a nodule over time in patients who had been diagnosed with LC. This was relevant
for the second task of identifying the malignant nodule. This was done by assessing nodule
morphology, growth pattern, and location; the only relevant information provided by the
Dutch Cancer Registry was the time of LC diagnosis and the lobe location. A confidence
score from 1 to 4 was used to determine the nodule most likely to be the LC: 1 indicated
benign morphology, 2 indicated uncertainty due to multiple nodules present, 3 indicated
suspicious morphology without a CT scan within 1 month of LC diagnosis, and 4 indicated
suspicious morphology with a CT scan within 1 month of LC diagnosis. Only nodules with
a score of 3 or 4 were included as cancer cases in this study.
Nodules were classified into one of four mutually exclusive subtypes: solid, part-solid,
ground-glass, or PFN. Part-solid and ground-glass nodules fall into the group of SSNs,
and the definition of a perifissural nodule—which show morphology indicative of benign
intrapulmonary lymph nodes—was that as defined by Hoop et al. [16].
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Only the CT features of each patient’s earliest scan were considered for the risk
prediction analysis. The derivation cohort included all eligible LC-free patients and the
eligible LC patients in which it could be said with high confidence that no malignant nodule
was retrospectively visible in the earliest scan. Some LC-free patients were diagnosed with
other cancer types which may have metastasized to the lungs. LC-free patients who were
highly suspect of having pulmonary metastatic disease were excluded.
2.3. Statistical Analysis
All statistical analysis was performed in the statistical program R version 3.6.3 [17].
Weighted Cox proportional hazards regression was performed [18], with LC diagnosis as
the event and the time between the earliest scan to LC diagnosis or the end of follow-up as
the time to event. Weights were determined based on Barlow’s estimate computing the Cox
model for case–cohort designs [19]. Since all patients diagnosed with LC were considered,
they were given a weight of 1. LC-free cases were given a weight of 37,085/1779 = 20.8,
i.e., the total number of LC-free cases in the full cohort divided by the number selected at
random. A Kaplan–Meier curve was plotted to visualize the time-dependent relationship
between nodule types present and LC incidence risk. The Kaplan–Meier curve was ad-
justed using rescaled inverse probability weighting based on the following untransformed
variables [18]: age, sex, emphysema, bronchitis, interstitial lung disease, lymphadenopathy,
aortic calcifications, and coronary calcifications.
Univariable analysis of all independent variables was performed first (Table 1). Trans-
formations of continuous variables with first- or second-degree factorial polynomials were
considered [20,21]; transformations were reverted if there were indications for model over-
fitting during interval validation. Multivariable regression of all variables (i.e., the Full
Model) is visualized in the form of a forest plot to indicate which predictors appear to
be strongest. To gauge the best predictive performance achievable without nodule-type
variables, a parsimonious multivariable model—in which variables which do not con-
tribute significantly to the model are excluded (p > 0.20)—containing only control variables
was derived (i.e., the Control Model). The backwards elimination procedure was used
for variable selection. Interaction terms between the largest nodule’s type and its mean
diameter were considered, but no interaction was found. Finally, a second parsimonious
model including nodule-type variables was derived (i.e., the Nodule Type Model) to assess
the added value of nodule-type information compared to the Control Model.
Results are presented in terms of hazard ratios with 95% confidence intervals. The
Schoenfeld global test was used to test the proportional hazards assumption [22]. In-
ternal validation was performed for each model by deriving new model coefficients on
1000 weighted bootstrap samples and calculating optimism as the difference between
the bootstrap model performance on the bootstrap sample and on the original cohort.
With the exception of determining variable inclusion in a parsimonious model, statistical
significance was defined as a p value of less than 0.05.
3. Results
We considered 186 LC patients and 711 LC-free patients from Center A and 292 LC
patients and 508 LC-free patients from Center B with adequate CT scans (Figure 1). The
malignant nodule was already visible in the earliest available scan in 315 of the 478 LC
patients, and 41 of the 1219 LC-patients were suspected of having pulmonary metastasis. In
total, 163 (34%) LC patients and 1178 (97%) LC-free patients were included in the derivation
cohort. The median time to end of follow-up or LC diagnosis was 1923 days (twenty-fifth
and seventy-fifth percentiles = 1148 and 2828 days). The patient and CT demographics are
summarized in Table 1.
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3.2. Parsimonious Lung Cancer Incidence Risk Models
Only “nodule diameter of the largest nodule” was excluded from the parsimonious
Control Model, leaving in age, sex, emphysema, bronchitis, interstitial lung disease, lym-
phadenopathy, aortic calcifications, and coronary calcifications (Table S2). Four nodule-
type variables were added to form the Nodule Type Model (Table 2): “solid nodule count”
(transformed), “part-solid nodule count”, “ground glass nodule count”, and “presence of a
perifissural nodule”, the latter indicating a lower future LC risk.
Table 2. Parsimonious lung cancer risk model (Nodule Type Model).
Variable Beta Coefficient Hazard Ratio (95%Confidence Interval) p Value
Patient characteristics
Age at earliest scan, per year
(((x−39)/10)2) 0.50255 1.65 (1.25 to 2.18) <0.001
Age at earliest scan, per year
(((x−39)/10)3) −0.13941 0.87 (0.82 to 0.93) <0.001
CT features excluding nodule type
Emphysema 0.70903 2.03 (1.33 to 3.12) 0.001
Bronchitis 0.39078 1.48 (0.95 to 2.29) 0.08
Interstitial lung disease 1.24998 3.49 (1.36 to 8.97) 0.009
Lymphadenopathy 0.54126 1.72 (1.06 to 2.93) 0.028
Aortic calcifications 0.57696 1.78 (1.08 to 2.93) 0.023
Coronary calcifications 0.51209 1.67 (1.04 to 2.69) 0.035
Nodule present 1.12291 3.07 (1.54 to 6.13) 0.001
Nodule type information
Solid nodule count, per nodule 1.39874 4.05 (1.30 to 12.63) 0.016
Solid nodule count, per nodule
((x + 1) × ln (x + 1)) −0.68170 0.51 (0.31 to 0.83) 0.007
Part-solid nodule count, per nodule 0.50634 1.66 (1.11 to 2.47) 0.013
Ground-glass nodule count, per nodule 0.41971 1.52 (1.06 to 2.17) 0.021
Perifissural nodule present −1.11383 0.33 (0.16 to 0.66) 0.002
A parsimonious model was derived using Cox regression containing only variables with a p value < 0.20 using backwards elimination.
Some variables were transformed as indicated by the mathematical expression in brackets, in which x represents the untransformed
variable. N/A: not applicable.
Given the finding that there may be a dose-dependent relationship between the
number of SSNs present in a scan, each cohort was divided into four groups: patients with
no nodules, patients with at least one nodule (none of which are SSNs), patients with a
single SSN, and patients with more than one SSN. The LC-free survival probability over
time of the groups was visualized as Kaplan–Meier curves (Figure 3). Among patients
with at least 5 years of LC-free follow-up or LC diagnosis within 5 years, LC incidence was
6% (23/379) in those without any nodules at baseline, increasing to 22% (67/300) in those
with at least one solid nodule (no subsolid nodules), 22% (18/82) in those with a single
SSN, and 40% (14/35) in those with at least two SSNs. The difference in LC-free survival
between the group without nodules and the other three groups was statistically significant
(log-rank test p < 0.001). The difference between having at least two SSNs compared to a
single SSN or only solid nodules was also significant (p = 0.05 and p = 0.03, respectively).
The LC probability between the single SSN and only solid nodules groups was equivalent
(p = 1.00). Weighted 5-year LC-free survival probabilities are given in the Figure 3 legend.
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Internal validation of the Nodule Type Model (Table 2) resulted in an area under the
receiver operating characteristic curve (AUC) of 0.827 (95% confidence band = 0.826 to 0.827)
on the original sample and 0.838 (0.837 to 0.838) on the bootstrap sample (optimism = 0.011).
The Control Model’s AUC was 0.802 (0.801 to 0.802) on the original sample and 0.811 (0.810
to 0.812) on the bootstrap sample (optimism = 0.009) (Table S2).
4. Discussion
Our research question was whether the nodule types present in a CT scan had pre-
dictive value for the development of LC in another location. To investigate this, we
performed weighted time-dependent regression analysis on a clinical case–cohort which
only included patients with LC-free baseline CT scans. This was necessary to ensure the
correct direction of causality: that the nodule types occurred before LC incidence. Age,
sex, and other quantitative CT information were included in the analysis to control for
potential confounding.
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One of the cohort’s inclusion criteria was a high level of certainty that lung cancer
was not (yet) detectable in the baseline scan. This can only be done retrospectively with
information from follow-up scans; the models and predictors described should be validated
and calibrated in a prospective clinical cohort.
Results of the univariable analysis and the Full Model revealed that the presence of
at least one solid nodule, part-solid nodule, or ground-glass nodule were significant risk
factors for future LC incidence (Table S1, Figure 2). Parsimonious models were derived to
simplify the interpretation by only considering the variables with the highest predictive
power (Table 2 and Table S2). The Nodule Type Model confirmed that the presence of
nodules is a risk factor for future LC development. Though this observation has been
previously described [4], a novel finding is that more part-solid and ground-glass nodules
increase the risk linearly, whereas more solid nodules (beyond one) reduces the risk. As
only 27 patients had more than two SSNs, it remains unclear whether the relationship is
indeed linear for higher SSN counts. The presence of at least one perifissural nodule was a
protective factor: its beta coefficient was equivalent in magnitude as that for the presence
of at least one nodule (−1.11 and 1.12, respectively, Table 2), indicating that patients with
nodules which are exclusively perifissural nodules have an equivalent risk to patients
without any nodules.
By calculating the difference in AUC performance between the parsimonious models
with and without nodule type information (Nodule Type Model and Control Model,
respectively), we found that the added value of nodule-type information was 0.025. Note
that the AUC is a summary measure that does not reflect clinical utility. To compensate,
time-to-event curves were plotted to visually display the trend of higher LC risk among
patients with more SSNs (Figure 3).
As would be expected from only including data from LC-free CT scans, the largest
nodule diameter was not a predictor of future malignancy in multivariable analysis. In
a scenario where LC may already be present, nodule size is otherwise established as
the strongest predictor of LC based on a single scan [9,23,24]. No interaction was found
between nodule type (i.e., solid vs. SSN) and nodule diameter.
The finding that the presence of an SSN may be a risk factor for future malignancy de-
velopment in another lung location has thus far been described only once, by Silva et al. [4],
based on results from the MILD screening population: of 389 screenees with at least one
SSN, 30 LCs were diagnosed, of which 22 were not derived from an SSN. In this context,
it is noteworthy that the same author group described an increased malignancy risk for
patients with an overall increased lung density, interpreted as an increased inflammatory
state [25].
We also found that greater numbers of solid nodules (beyond one) are indicative of
lower LC risk. A possible explanation is that some patients naturally develop more solid
nodules with no clinical significance. Most benign solid nodules are small (i.e., <6 mm)
and represent benign entities [26]; not including small solid nodules in the count may
counteract this finding. Note that there is a moderate inter-rater agreement when classifying
solid nodules as perifissural nodules [27], and a lack of a standardized definition [14].
Therefore, there may have been an insufficient distinction between small solid nodules
and perifissural nodules. We expect that a considerable number of these solid nodules
could also be classified as perifissural nodules, of which the LC risk can be considered
negligible [14].
The clinical implication of our results is that future LC risk models should consider
incorporating SSN count. Such models would likely be most useful in a LC screening
setting for the purpose of personalizing scan intervals. As our results were derived from
a clinical cohort, subsequent research should first attempt to replicate our findings in a
high-risk screening population. Although the predictive value of nodule-type information
alone appears to be relatively small, it can be significant when applied to large numbers.
To the best of our knowledge, no lung cancer risk model has yet considered the number of
SSNs and solid nodules as variables [28]. Schreuder et al. [23] included the “presence of
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non-solid nodule” and “presence of part-solid nodule” in their parsimonious model for
determining whole scan-based risk, but did not count the SSNs.
Another finding was that radiologist-rated presence of emphysema, bronchitis, in-
terstitial lung disease, lymphadenopathy, calcifications of the coronary arteries, and calci-
fications of the transthoracic aorta are non-nodule CT features which contributed to LC
prediction accuracy. This supports the notion that the presence of chronic obstructive
pulmonary disease and/or cardiovascular disease may indicate susceptibility for LC, likely
due to exposure to overlapping risk factors [24,29–33]. Note that while the presence of
emphysema, coronary calcifications, and aorta calcifications was originally classified as
“none”, “mild”, “moderate”, or “severe”, no statistically significant trends were found
with increasing severity (results not shown); this was why these variables were converted
into binary form for the analysis. While the relationship between these variables with LC
incidence is unlikely to be linear [24], it is unclear whether quantitative CT measures would
have been better predictors compared to clinician-reported outcome measures.
Limitations
Our study has other limitations that should be taken into consideration. First, no
data on smoking status or intensity were available, which would have been a strong
demographic predictor of LC and may have been informative as a control variable or to
select a higher risk population equivalent to that in a screening setting [34]. Data on patient
mortality were also lacking, preventing the investigation of potential differences in LC
prognosis; a higher LC risk does not imply a poorer prognosis [35]. Only the size of the
largest nodule was considered for the model to avoid overfitting and to simplify model
interpretation. The risk models only considered the earliest scan, from which it is not
possible to derive information on nodule growth and whether nodules are transient or
persistent. Finally, it is possible that the follow-up time was not sufficiently long, and that
some LC nodules were erroneously deemed to be benign in our study.
5. Conclusions
In conclusion, our results indicate that the presence of single time-point SSNs on CT
in a clinical setting may be a risk factor for future LC development in another lung location
in a dose-dependent manner. The risk may increase linearly with the number of SSNs. This
finding highlights the potential importance of utilizing information from the entire CT scan
to improve the accuracy of LC risk assessment, and work towards personalized medicine.
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